Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
OBJECTIVE: To describe the treatment outcomes of patients receiving dolutegravir (DTG) in a 'real-world setting' in Belgium. DESIGN: Retrospective, observational, multicenter cohort. METHODS: Inclusion criteria: HIV-1 patients at least 18 years old having received DTG as part of their combined antiretroviral therapy (cART) between 1 April 2014 and 1 December 2017. Primary endpoint: rate of virologic suppression, defined as plasma HIV-1 viral load less than 50 copies/ml, at weeks 24, 48, and 96. Secondary endpoints: durability, expressed as probability of experiencing loss of virologic suppress... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Verlag/Hrsg.: |
Lippincott Williams & Wilkins
|
Schlagwörter: | Adult / Aged / Antiretroviral Therapy / Highly Active / Belgium / Female / HIV Infections / HIV Integrase Inhibitors / HIV-1 / Heterocyclic Compounds / 3-Ring / Humans / Male / Middle Aged / Neuropsychology / Oxazines / Piperazines / Pyridones / Retrospective Studies / Treatment Outcome / Viral Load / Weight Gain |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26915482 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/251925 |